Global Nanoparticles in Biosciences Market 2022-2028

June 2022 | 62 pages | ID: G965793996ECEN
Gen Consulting Company

Abstracts

Nanoparticles can be engineered with distinctive compositions, sizes, shapes, and surface chemistries to enable novel techniques in a wide range of biological applications. The global nanoparticles in biosciences market size is projected to grow by USD 48 billion from 2022 to 2028, registering a CAGR of 7.7 percent, according to a new report by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global nanoparticles in biosciences market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the nanoparticles in biosciences industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, and region. The global market for nanoparticles in biosciences can be segmented by product: drug delivery systems, drug development and formulation, others. The drug delivery systems segment captured the largest share of the market in 2021. Nanoparticles in biosciences market is further segmented by region: Asia Pacific, Europe, North America, Rest of the World (RoW). North America held the largest share of the global nanoparticles in biosciences market in 2021 and is anticipated to hold its share during the forecast period.

By product:

• drug delivery systems
• drug development and formulation
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The global nanoparticles in biosciences market report offers detailed information on several market vendors, including Bristol Myers Squibb Company (BMS), Camurus AB, F. Hoffmann-La Roche AG, GlaxoSmithKline plc (GSK), Merck KGaA, NanoCarrier Co., Ltd., Novartis International AG, among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global nanoparticles in biosciences market.
• To classify and forecast the global nanoparticles in biosciences market based on product, region.
• To identify drivers and challenges for the global nanoparticles in biosciences market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global nanoparticles in biosciences market.
• To identify and analyze the profile of leading players operating in the global nanoparticles in biosciences market.

Why Choose This Report

• Gain a reliable outlook of the global nanoparticles in biosciences market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.

Contents

PART 1. INTRODUCTION

Report description
Objectives of the study
Market segment
Years considered for the report
Currency
Key target audience

PART 2. METHODOLOGY

PART 3. EXECUTIVE SUMMARY

PART 4. MARKET OVERVIEW

Introduction
Drivers
Restraints
Impact of COVID-19 pandemic

PART 5. MARKET BREAKDOWN BY PRODUCT

Drug delivery systems
Drug development and formulation
Others

PART 6. MARKET BREAKDOWN BY REGION

Asia Pacific
Europe
North America
Rest of the World (RoW)

PART 7. KEY COMPANIES

Bristol Myers Squibb Company (BMS)
Camurus AB
F. Hoffmann-La Roche AG
GlaxoSmithKline plc (GSK)
Merck KGaA
NanoCarrier Co., Ltd.
Novartis International AG
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES
DISCLAIMER